Dashboard
1
Poor Management Efficiency with a low ROCE of 4.19%
- The company has been able to generate a Return on Capital Employed (avg) of 4.19% signifying low profitability per unit of total capital (equity and debt)
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.57
3
Poor long term growth as Operating profit has grown by an annual rate -281.20% of over the last 5 years
4
With a growth in Net Profit of 122.24%, the company declared Very Positive results in Jun 25
5
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
JPY 5,810 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.13
-3.72%
1.54
Revenue and Profits:
Net Sales:
1,231 Million
(Quarterly Results - Jun 2025)
Net Profit:
-67 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.5%
0%
-9.5%
6 Months
-11.71%
0%
-11.71%
1 Year
-29.02%
0%
-29.02%
2 Years
-31.95%
0%
-31.95%
3 Years
-61.49%
0%
-61.49%
4 Years
-63.58%
0%
-63.58%
5 Years
-82.36%
0%
-82.36%
Precision System Science Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.76%
EBIT Growth (5y)
-281.20%
EBIT to Interest (avg)
1.57
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.72
Tax Ratio
0.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.19%
ROE (avg)
2.77%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.53
EV to EBIT
-12.96
EV to EBITDA
-38.00
EV to Capital Employed
1.65
EV to Sales
1.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.70%
ROE (Latest)
-11.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,230.60
1,264.80
-2.70%
Operating Profit (PBDIT) excl Other Income
25.70
83.90
-69.37%
Interest
5.30
5.70
-7.02%
Exceptional Items
-23.80
-65.30
63.55%
Consolidate Net Profit
-66.90
-30.10
-122.26%
Operating Profit Margin (Excl OI)
-30.50%
21.60%
-5.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.70% vs 13.11% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -122.26% vs 60.70% in Mar 2025
Annual Results Snapshot (Consolidated) - Jun'25
Jun'25
Jun'24
Change(%)
Net Sales
4,692.60
3,980.00
17.90%
Operating Profit (PBDIT) excl Other Income
116.60
-547.20
121.31%
Interest
20.50
31.60
-35.13%
Exceptional Items
-113.10
-83.30
-35.77%
Consolidate Net Profit
-253.10
-1,121.50
77.43%
Operating Profit Margin (Excl OI)
-25.90%
-240.30%
21.44%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2025 is 17.90% vs -24.60% in Jun 2024
Consolidated Net Profit
YoY Growth in year ended Jun 2025 is 77.43% vs 15.31% in Jun 2024
About Precision System Science Co., Ltd. 
Precision System Science Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






